[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@tom_the_bomb__ ⛏🅾️Ⓜ️💣

⛏🅾️Ⓜ️💣 posts on X about $8750t, $4568t, $6417t, $323m the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX -XX%
• X Month XXXXXX -XX%
• X Months XXXXXXX -XXXX%
• X Year XXXXXXX -XX%

Mentions: X #

• X Week XX -XX%
• X Month XX -XX%
• X Months XXX +41%
• X Year XXX +8.10%

Followers: XXXXX #

• X Week XXXXX +0.18%
• X Month XXXXX +1.10%
• X Months XXXXX +2.80%
• X Year XXXXX +4.20%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence stocks XX% finance XX%

Social topic influence $8750t #17, $4568t #4, $6417t #9, $323m 20%, $1004m #1, $1034m 20%, $236b 20%, $425m 20%, $1322m 20%, $3337m #1

Top accounts mentioned or mentioned by @kirranejam60371 @avacta @bigcheese88930 @asininitybeyond @arianacar58927 @stevenr50537052 @john_lancs

Top assets mentioned Novartis AG (NVS)

Top Social Posts

Top posts by engagements in the last XX hours

"A recent disclosure caught my eye. A leading #oncology KOL listed research funding and personal advisory work for: Daiichi Sankyo ✅ AstraZeneca ✅ Pfizer ✅ Genentech ✅ Seagen ✅ BioNTech ✅ and. #AVCT ✅ She's (1) respected (2) strategically influential and (3) trusted in early phase and ADC decision making. On the MSKCC page it doesnt mention Avacta so Im assuming this is a recent addition potentially linked to the upcoming AVA6103 programme given her breast cancer/TNBC specialism. This type of KOL usually consults for the top tier ADC/oncology players. So it's very good to see @avacta in the"
X Link 2025-11-30T21:38Z 3366 followers, 4112 engagements

"AVA6000 sales ( only scaled market penetration): In X years: STS: $323m SGC: $1004m TNBC: $1034m ---- TOTAL: $2.36B ---- In X years: STS: $425m SGC: $1322m TNBC: $3337m ---- TOTAL: $5.08B ---- #AVCT"
X Link 2025-11-28T09:45Z 3365 followers, 8476 engagements

"Daiichi Sankyo Seagen Pfizer Novartis and Merck are names that have consistently surfaced whenever deal rumours have appeared. When one of them steps forward it changes everything. Look forward to the RNS that finally shows where the smart money has landed. #AVCT"
X Link 2025-12-02T08:54Z 3364 followers, 13K engagements

"We have to start with what 6000 is worth. We may as well use the peel hunt figures for STS SGC and TNBC in only: Year 5: STS: $323M SGC: $1004M TNBC: $1034M = $2.36B Year 9: STS: $425m SGC: $1322M TNBC: $3337M = $5.08B Thats one drug one geography and zero credit for: Pricing uplift Label expansion into ovarian cancer Combination therapy Excluding non- markets Lifecycle extensions No FDA ODD Platform optionality Etc. BP typically pays 5-10x peak sales for a late stage asset with clear differentiation. 6000 is projecting $5B peak sales for X indications (exc the larger HER2+ & HER+"
X Link 2025-12-09T21:32Z 3366 followers, XXX engagements

"If Biotechs rarely follow a normal path the only constant is good tech leads to partnershipsorbuyouts what happens if you have groundbreaking tech #AVCT #Biotech #Buyout"
X Link 2025-12-10T08:08Z 3366 followers, 2262 engagements